Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
(Thomson Reuters ONE) -
Novartis International AG /
Novartis convenes experts to discuss new technologies in healthcare at Novartis
International BioCamp
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* 13th International Biotechnology Leadership Camp focuses on potential of new
technologies to fundamentally transform biomedical research and the
pharmaceutical business
* Interactive program brings 60 top university students from 18 countries and
territories to Novartis headquarters in Switzerland
* Over the course of three days, students will attend lectures, visit labs and
work on a business case exploring opportunities of using digital
technologies in healthcare
Basel, August 29, 2016 - Novartis today opened the 13th International
Biotechnology Leadership Camp (BioCamp). Over the course of three days more than
60 selected students from international universities will discuss and explore
with biotechnology and business experts how patients around the world can
benefit from innovative technologies.
The digital age has the potential to fundamentally transform biomedical research
and the pharmaceutical business. At BioCamp, students and experts will explore
these opportunities and discuss ways in which this can benefit patients around
the world.
"As a leader in healthcare innovation, Novartis aims to leverage the fundamental
transformation that the digital age will bring for biomedical research. This
will bring great change to the pharmaceutical industry and is in the best
interests of patients and society," said Joseph Jimenez, CEO of Novartis.
"Digitalization can foster progress in research and development, make clinical
trials more efficient and patient-friendly and allow us to better understand who
benefits most from which therapies."
Neuroscience is one of the areas where digital innovation is revolutionizing
medical practice. An example highlighted at the event is an innovative movement
recording system which aims to quantify a multiple sclerosis (MS) patient's
level of disability in a non-invasive, patient-friendly manner. The device
measures a patient's movements using a video sensor with machine learning
algorithms. Currently under development by Novartis in collaboration with
leading MS experts and Microsoft Research, this tool may have the potential to
change how neurological dysfunction and disability progression are assessed in
MS patients.
This new device will also be the basis of a workshop, where BioCamp participants
will work in groups to develop strategies to successfully include this new
technology in a clinical setting. On the final day of the program, the groups
will present their strategy proposals to a jury of experts. The jury will select
three individual winners and one winning team based on their contribution,
performance, leadership and teamwork. The workshop will give students first-hand
experience of working in a diverse cross-cultural project team.
About BioCamp
The Novartis International Biotechnology Leadership Camp is a 3-day
biotechnology seminar for top graduate and postgraduate students interested in
pursuing a career in biotechnology.
BioCamp participants get an insider's perspective on the challenges and
opportunities in biotechnology today through seminars led by Novartis leaders
and experts from around the world. Workshops are designed to give participants
the tools they need to become successful biotech managers and entrepreneurs.
Launched in 2003 in Taiwan, BioCamp has developed into an international forum
for science and business students from around the world to learn, exchange ideas
and work together in a highly competitive business environment. Today's seminar
marks the seventh international BioCamp hosted at the state-of-the-art Novartis
global headquarters in Basel, Switzerland.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "opportunities," "potential," "will," "can," "aims," "under
development," "may," "designed," or similar terms, or by express or implied
discussions regarding potential approvals for the movement recording system
under development, or regarding potential future revenues from such system. You
should not place undue reliance on these statements. Such forward-looking
statements are based on the current beliefs and expectations of management
regarding future events, and are subject to significant known and unknown risks
and uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that the movement recording system under development
will be submitted or approved for sale in any market, or at any particular time.
Nor can there be any guarantee that such system will be commercially successful
in the future. In particular, management's expectations regarding such system
could be affected by, among other things, the uncertainties inherent in research
and development, including unexpected clinical trial results and additional
analysis of existing clinical data; unexpected regulatory actions or delays or
government regulation generally; the company's ability to obtain or maintain
proprietary intellectual property protection; general economic and industry
conditions; global trends toward health care cost containment, including ongoing
pricing pressures; unexpected safety, quality or manufacturing issues, and other
risks and factors referred to in Novartis AG's current Form 20-F on file with
the US Securities and Exchange Commission. Novartis is providing the information
in this press release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2015, the Group achieved net
sales of USD 49.4 billion, while R&D throughout the Group amounted to
approximately USD 8.9 billion (USD 8.7 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 118,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Patrick Barth Satoshi Sugimoto
Novartis Global Media Relations Communications Switzerland
+41 61 696 6273 (direct) +41 61 324 61 29 (direct)
+41 79 732 0801 (mobile) +41 79 619 20 35 (mobile)
patrick.barth(at)novartis.com satoshi.sugimoto(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/2037651/759279.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 29.08.2016 - 07:15 Uhr
Sprache: Deutsch
News-ID 491422
Anzahl Zeichen: 8824
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 284 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
